Digestive Diseases and Sciences

, Volume 54, Issue 2, pp 328–332 | Cite as

The Effect of Gastroesophageal Flap Valve Appearance on the Management of Patients with Symptoms of Gastroesophageal Reflux Disease

  • Elias Xirouchakis
  • Dimitrios Kamberoglou
  • Dimitrios Kalos
  • Evanthia Zambeli
  • Vassilios Doulgeroglou
  • Vassilios Tzias
Original Article


Purpose To assess the effectiveness of anti-reflux treatment in gastroesophageal reflux disease patients classified according to esophagogastric junction morphology (Hill classification). Results A symptom score and endoscopic grading of gastrooesophageal flap valve appearance were determined in 49 symptomatic patients (female 26, male 23; mean age 49 years, range 21–76 years). Patients received 8 weeks of continuous rabeprazole at a daily dose of 20 mg and, upon symptom control, continued with on-demand treatment for 3 months. The mean symptom score at 8 weeks was significantly reduced in all groups. However, at the end of the on-demand therapy, patients with Hill grade IV had used more rabeprazole tablets than those in the two other groups (II: 10.86 ± 14.52, III: 14.73 ± 14.58, IV: 25.78 ± 15.85; P = 0.002). Conclusions Continuous treatment is effective in all groups of patients with reflux disease. Grading patients according to the gastroesophageal flap valve appearance is useful as a prognostic factor, especially when on-demand therapy is considered to be an option.


Flap valve Gastroesophageal reflux disease On-demand treatment Proton pump inhibitors Rabeprazole 


  1. 1.
    Locke GR III, Talley NJ, Fett SL et al (1997) Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 112(5):1448–1456. doi: 10.1016/S0016-5085(97)70025-8 PubMedCrossRefGoogle Scholar
  2. 2.
    Heading RC (1999) Prevalence of upper gastrointestinal symptoms in the general population: a systematic review. Scand J Gastroenterol Suppl 231:3–8. doi: 10.1080/003655299750025200 PubMedCrossRefGoogle Scholar
  3. 3.
    Lind T, Havelund T, Carlsson R et al (1997) Heartburn without esophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 32(10):974–979. doi: 10.3109/00365529709011212 PubMedCrossRefGoogle Scholar
  4. 4.
    Fass R (2003) Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 98[Suppl 3]:S2–S7. doi: 10.1016/S0002-9270(03)00009-1 PubMedCrossRefGoogle Scholar
  5. 5.
    van Herwaarden MA, Samsom M, Smout AJ (2004) The role of hiatus hernia in gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 16(9):831–835. doi: 10.1097/00042737-200409000-00003 PubMedCrossRefGoogle Scholar
  6. 6.
    Kahrilas PJ, Lin S, Chen J et al (1999) The effect of hiatus hernia on gastro-oesophageal junction pressure. Gut 44(4):476–482PubMedGoogle Scholar
  7. 7.
    Hill LD, Kozarek RA, Kraemer SJ et al (1996) The gastroesophageal flap valve: in vitro and in vivo observations. Gastrointest Endosc 44(5):541–547. doi: 10.1016/S0016-5107(96) 70006-8 PubMedCrossRefGoogle Scholar
  8. 8.
    Chiba N, De Gara CJ, Wilkinson JM et al (1997) Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 112(6):1798–1810. doi: 10.1053/gast.1997.v112.pm9178669 PubMedCrossRefGoogle Scholar
  9. 9.
    Cloud ML, Enas N, Humphries TJ et al (1998) Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose–response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. Dig Dis Sci 43(5):993–1000. doi: 10.1023/A:1018822532736 PubMedCrossRefGoogle Scholar
  10. 10.
    Robinson M (2004) Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders. Aliment Pharmacol Ther 20[Suppl 6]:30–37. doi: 10.1111/j.1365-2036.2004.02163.x PubMedCrossRefGoogle Scholar
  11. 11.
    Bour B, Staub JL, Chousterman M et al (2005) Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment Pharmacol Ther 21(7):805–812. doi: 10.1111/j.1365-2036.2005.02413.x PubMedCrossRefGoogle Scholar
  12. 12.
    Metz DC, Inadomi JM, Howden CW et al (2007) On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol 102(3):642–653. doi: 10.1111/j.1572-0241.2006.00998.x PubMedCrossRefGoogle Scholar
  13. 13.
    Pace F, Tonini M, Pallotta S et al (2007) Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken ‘on-demand’. Aliment Pharmacol Ther 26(2):195–204PubMedCrossRefGoogle Scholar
  14. 14.
    Frazzoni M, De ME, Grisendi A et al (2002) Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression. Aliment Pharmacol Ther 16(5):881–886. doi: 10.1046/j.1365-2036.2002.01248.x PubMedCrossRefGoogle Scholar
  15. 15.
    Gordon C, Kang JY, Neild PJ et al (2004) The role of the hiatus hernia in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 20(7):719–732. doi: 10.1111/j.1365-2036.2004.02149.x PubMedCrossRefGoogle Scholar
  16. 16.
    Castell DO, Murray JA, Tutuian R et al (2004) Review article: the pathophysiology of gastro-oesophageal reflux disease—oesophageal manifestations. Aliment Pharmacol Ther 20[Suppl 9]:14–25. doi: 10.1111/j.1365-2036.2004.02238.x PubMedCrossRefGoogle Scholar
  17. 17.
    Contractor QQ, Akhtar SS, Contractor TQ (1999) Endoscopic esophagitis and gastroesophageal flap valve. J Clin Gastroenterol 28(3):233–237. doi: 10.1097/00004836-199904000-00009 PubMedCrossRefGoogle Scholar
  18. 18.
    Carlsson R, Dent J, Watts R et al (1998) Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 10(2):119–124. doi: 10.1097/00042737-199802000-00004 PubMedCrossRefGoogle Scholar
  19. 19.
    Jones MP, Sloan SS, Rabine JC et al (2001) Hiatal hernia size is the dominant determinant of esophagitis presence and severity in gastroesophageal reflux disease. Am J Gastroenterol 96(6):1711–1717. doi: 10.1111/j.1572-0241.2001.03926.x PubMedCrossRefGoogle Scholar
  20. 20.
    Oberg S, Peters JH, DeMeester TR et al (1999) Endoscopic grading of the gastroesophageal valve in patients with symptoms of gastroesophageal reflux disease (GERD). Surg Endosc 13(12):1184–1188. doi: 10.1007/PL00009617 PubMedCrossRefGoogle Scholar
  21. 21.
    Lin BR, Wong JM, Chang MC et al (2006) Abnormal gastroesophageal flap valve is highly associated with gastroesophageal reflux disease among subjects undergoing routine endoscopy in Taiwan. J Gastroenterol Hepatol 21(3):556–562. doi: 10.1111/j.1440-1746.2005.04003.x PubMedCrossRefGoogle Scholar
  22. 22.
    Kim GH, Kang DH, Song GA et al (2006) Gastroesophageal flap valve is associated with gastroesophageal and gastropharyngeal reflux. J Gastroenterol 41(7):654–661. doi: 10.1007/s00535-006-1819-9 PubMedCrossRefGoogle Scholar
  23. 23.
    Takeuchi R, Kato K, Mizuno S et al (2004) Abnormal gastroesophageal flap valve is highly associated with endoscopic reflux esophagitis after Helicobacter pylori eradication. Helicobacter 9(1):1–8. doi: 10.1111/j.1083-4389.2004.00193.x PubMedCrossRefGoogle Scholar
  24. 24.
    Pandolfino JE, Bianchi LK, Lee TJ et al (2004) Esophagogastric junction morphology predicts susceptibility to exercise-induced reflux. Am J Gastroenterol 99(8):1430–1436. doi: 10.1111/j.1572-0241.2004.30515.x PubMedCrossRefGoogle Scholar
  25. 25.
    Ponce J, Arguello L, Bastida G et al (2004) On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Dig Dis Sci 49(6):931–936. doi: 10.1023/B:DDAS.0000034551.39324.c3 PubMedCrossRefGoogle Scholar
  26. 26.
    Hungin AP, Rubin G, O’Flanagan H (1999) Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 49(443):463–464PubMedGoogle Scholar
  27. 27.
    Gerson LB, Robbins AS, Garber A et al (2000) A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 95(2):395–407. doi: 10.1111/j.1572-0241.2000.01759.x PubMedCrossRefGoogle Scholar
  28. 28.
    Lind T, Havelund T, Lundell L et al (1999) On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis—a placebo-controlled randomized trial. Aliment Pharmacol Ther 13(7):907–914. doi: 10.1046/j.1365-2036.1999.00564.x PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Elias Xirouchakis
    • 1
  • Dimitrios Kamberoglou
    • 1
  • Dimitrios Kalos
    • 1
  • Evanthia Zambeli
    • 1
  • Vassilios Doulgeroglou
    • 1
  • Vassilios Tzias
    • 1
  1. 1.GI Endoscopy Department1st IKA HospitalMelissia, AthensGreece

Personalised recommendations